Mobile website
Prompt Report
Clinical efficacy of activated-HLA haploidentical peripheral blood stem cells in treatment of advanced solid tumors
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the antitumor and side effects of activatedHLA haploidentical peripheral blood tem cells (haploPBSCs) in the treatment of advanced refractory solid tumor patients. Methods:Fortytwo patients with advanced refractory tumor, who were diagnosed in our hospital from Oct. 2004 to Oct. 2007, were enrolled in this study (all patients signed informed consent), including 12 with ovarian cancer, 9 with renal cancer, 8 with lung cancer, 8 with breast cancer, 2 with colon cancer, 2 with gastric cancer, and 1 with melanoma. The donors were healthy direct relatives of the patients; the donors’ haploPBSCs were mobilized, collected, and activated by rhIL2 in vitro. The clinical efficacy and side effects of haploPBSCs therapy were assessed by CT/PETCT scanning, RESIST standard, KPS score, and clinical response rates, etc. Results:All 42 patients received one episode of haploPBSCs treatment. The progressionfree survivals (PFS) were 6 months and the clinical beneficial rate (CR+PR+SD) was 73.8%. The beneficial rate of life quality was 76.2% and the KPS increased by 20 (030) points on average after haploPBSCs treatment. The patients with KIR unmatched in GVH direction had better outcomes than those with KIR matched or KIR unmatched in HVG direction (P<005), and the clinical beneficial rate, PFS and total beneficial rate were 94.1% vs 60.0%, (13.4±1.3) vs (80±09) months, and 89.5% vs 65.2%, respectively (all P<0.05). The donor/recipient relation as the mother/child had a better outcome than that as the father/child (P<0.05). Patients with renal cancer or ovarian cancer had better outcomes than those with other cancers, with clinical beneficial rates being 90.0% and 81.8%, respectively. Conclusion: Activated haploPBSCs therapy can induce nonspecific antitumor effect, and improve the clinical symptom and life quality of advanced tumor patients.
Keywords:
Project Supported:
Project supported by the National “the 10th Five Years Plan” of Science and Technology Key Program of China (No. 2005BA740C), and the Science and Technology Innovation Program of Tianjin (No. 06FZZDSF01500)
Clc Number:
